Skip to main content
. 2021 May 14;11:538927. doi: 10.3389/fonc.2021.538927

Figure 4.

Figure 4

Comparison of the expression and promoter methylation level of TERT between cancer samples and matched normal bladder samples in the TCGA-BLCA cohort. (A) The TERT mRNA expression was significantly higher in 408 BLCA samples than in 19 normal bladder samples (P <0.001). (B) The TERT mRNA expression was significantly higher in BLCA samples from Caucasian, African–American, Asian than in normal bladder samples (Normal VS Caucasian: P <0.001, Normal VS African–American: P <0.001, Normal VS Asian: P = 0.008, Caucasian VS African–American: P = 0.450, Caucasian VS Asian: P = 0.031, African–American VS Asian: P = 0.024). (C) The promoter methylation level of TERT was significantly higher in 418 BLCA samples than in 21 normal bladder samples (P <0.001). The Beta value: 0.5–0.7 was considered hyper-methylation while the Beta value: 0.25–0.3 was considered to indicate hypo-methylation. (D) The promoter methylation level of TERT was significantly higher in BLCA samples from Caucasian, African–American, Asian than in normal bladder samples (Normal VS Caucasian: P <0.001, Normal VS African–American: P <0.001, Normal VS Asian: P <0.001, Caucasian VS African–American: P = 0.737, Caucasian VS Asian: P = 0.240, African–American VS Asian: P = 0.604). BLCA, bladder urothelial carcinoma.